Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2026-01-03 @ 5:42 AM
Study NCT ID:
NCT00715403
Status:
COMPLETED
Last Update Posted:
2014-12-02
First Post:
2008-07-11
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Sponsor:
Boehringer Ingelheim
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
1199.16
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Boehringer Ingelheim, Study Chair
Old Organization:
Boehringer Ingelheim